Vanda Pharmaceuticals and AnaptysBio have announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully...
Jabil has acquired of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early stage, clinical, and commercial volume aseptic filling,...
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' JOURNAVX (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the...